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o r i g i n a l a r t i c l e
A Novel Risk Factor Associated With Colonization by
Carbapenemase-Producing Enterobacteriaceae: Use of Proton Pump
Inhibitors in Addition to Antimicrobial Treatment
Vincent C. C. Cheng, MD;1,2 Jonathan H. K. Chen, PhD;1 Simon Y. C. So, MMedSc;1 Sally C. Y. Wong, FRCPath;1
Pui-Hing Chau, PhD;3 Lisa M. W. Wong, MSc(IC);2 Radley H. C. Ching, BSN;2 Modissa M. L. Ng, MSN;2
Wan-Mui Lee, MSN;2 Ivan F. N. Hung, MD;4 Pak-Leung Ho, MD;1 Kwok-Yung Yuen, MD1
objective. To study the association between gastrointestinal colonization of carbapenemase-producing Enterobacteriaceae (CPE) and
proton pump inhibitors (PPIs).
methods. We analyzed 31,526 patients with prospective collection of fecal specimens for CPE screening: upon admission (targeted
screening) and during hospitalization (opportunistic screening, safety net screening, and extensive contact tracing), in our healthcare network
with 3,200 beds from July 1, 2011, through December 31, 2015. Specimens were collected at least once weekly during hospitalization for CPE
carriers and subjected to broth enrichment culture and multiplex polymerase chain reaction.
results. Of 66,672 fecal specimens collected, 345 specimens (0.5%) from 100 patients (0.3%) had CPE. The number and prevalence
(per 100,000 patient-days) of CPE increased from 2 (0.3) in 2012 to 63 (8.0) in 2015 (P< .001). Male sex (odds ratio, 1.91 [95% CI, 1.15–3.18],
P= .013), presence of wound or drain (3.12 [1.70–5.71], P< .001), and use of cephalosporins (3.06 [1.42–6.59], P= .004), carbapenems
(2.21 [1.10–4.48], P= .027), and PPIs (2.84 [1.72–4.71], P< .001) in the preceding 6 months were signiﬁcant risk factors by multivariable
analysis. Of 79 patients with serial fecal specimens, spontaneous clearance of CPE was noted in 57 (72.2%), with a median (range) of 30 (3–411)
days. Comparing patients without use of antibiotics and PPIs, consumption of both antibiotics and PPIs after CPE identiﬁcation was associated
with later clearance of CPE (hazard ratio, 0.35 [95% CI, 0.17–0.73], P= .005).
conclusions. Concomitant use of antibiotics and PPIs prolonged duration of gastrointestinal colonization by CPE.
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Carbapenemase-producing Enterobacteriaceae (CPE) are
emerging multidrug-resistant gram-negative organisms caus-
ing an unprecedented public health threat.1 Therapeutic
options for invasive infections are limited and the mortality of
bloodstream infection caused by CPE is up to 37%.2 The
nature of plasmid-mediated carbapenemases such as class A
enzymes of the KPC type, zinc-dependent class B metallo-
β-lactamases of mainly NDM, IMP, and VIM types, and class
D carbapenemase of OXA-48 type facilitates global transmis-
sion and causes numerous outbreaks of CPE in the healthcare
settings.3–5 Failure in recognizing asymptomatic carriers may
result in nosocomial transmission6 or even country-wide
outbreak.7 Therefore, enhanced infection control measures
such as active surveillance, isolation and cohorting of CPE
patients with dedicated nursing staff and medical equipment,
and daily bathing with chlorhexidine gluconate have been
implemented to control the spread of CPE in the endemic
settings.8
Compared with the global epidemiology, CPE is not yet
endemic in Hong Kong and mainland China.9,10 It is impor-
tant to prevent importation and nosocomial transmission of
CPE in our healthcare settings through the implementation of
proactive infection control measures11 and to understand
the risk factors for CPE acquisition, such as recent hospitali-
zation and the presence of indwelling devices.12 Here, we
analyzed the risk factors and duration of CPE colonization
among the ﬁrst 100 patients with gastrointestinal colonization
of CPE in our healthcare network. Unexpectedly, the use of
proton pump inhibitors (PPIs) was independently associated
with fecal colonization and carriage duration of CPE. The
ﬁnding is important for the formulation of infection control
policy.
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methods
Setting
As part of the routine hospital surveillance to control CPE, we
analyzed the microbiologic and epidemiologic ﬁndings of
gastrointestinal colonization of carbapenem-resistant
Enterobacteriaceae (CRE) and CPE in a healthcare network
(Hong Kong West Hospital Network) that comprises an acute
care university-afﬁliated teaching hospital with 1,600 beds as
well as 3 extended-care hospitals with another 1,600 beds in
Hong Kong. According to our infection control program,
patients were prospectively screened for CPE in target admis-
sion screening, opportunistic screening, safety net screening,
and extensive contact tracing during hospitalization as pre-
viously described.11,13,14 The duration of gastrointestinal
colonization was monitored in patients colonized with CPE by
surveillance fecal specimens collected at least once weekly, or
more frequently if clinically indicated. The duration of carriage
was taken as the date of the ﬁrst positive to the date of CPE
clearance. Clearance of CPE was assumed if a patient had at
least 2 consecutive negative cultures taken 48 hours apart. To
ensure fecal specimens were collected from all patients meet-
ing the criteria, an electronic ﬁle of patient data was auto-
matically generated by the hospital record ofﬁce and was
passed onto the infection control team on each working day.
Newly admitted patients who fulﬁlled the screening criteria
and those patients who had been hospitalized for 14 days were
highlighted in the electronic ﬁle, which was further compared
with the registration data of fecal specimens received for CPE
screening in the laboratory information system in the micro-
biology laboratory. For patients who met the CPE screening
criteria but had no fecal specimen received by the laboratory
according to the system, the infection control nurses would
remind the frontline staff for specimen collections. Usually,
rectal swabs were collected for targeted screening, safety net
screening, and extensive contact tracing, whereas stool
specimens requested for Clostridium difﬁcile were screened
routinely for CPE (opportunistic screening).
Upon identiﬁcation of gastrointestinal colonization of CPE,
infection control nurses would advise appropriate infection
control measures as described previously.11,15–17 Brieﬂy,
patients were placed in single-room isolation with strict con-
tact precautions. Cleaning staff was speciﬁcally trained to
perform meticulous disinfection of high-touch areas, such as
bedrail, bedside table, and locker.18 Terminal cleansing of
patients’ rooms and change of curtains were performed during
their discharge or transfer.
Epidemiologic characteristics of all patients with newly
identiﬁed CPE were retrieved from the clinical management
system, which is a computer database with patients’ informa-
tion accessible from all public hospitals in Hong Kong. Risk
factors for gastrointestinal colonization of CPE were investi-
gated by case-control analysis. Two consecutive patients before
and after a CPE case with negative result of CRE and CPE were
chosen as controls. Nosocomial onset of CPE was deﬁned as a
positive culture of CPE identiﬁed by opportunistic screening
performed after 48 hours of hospitalization, or safety net
screening on the 14th day of hospitalization, whereas noso-
comial acquisition of CPE was deﬁned as secondary CPE cases
identiﬁed during contact tracing. Outbreak investigations were
conducted when 3 or more epidemiologically linked patients
(same ward) with nosocomial onset or acquisition of CPE was
identiﬁed. This study was approved by the institutional review
board of the University of Hong Kong/Hospital Authority
Hong Kong West Hospital Cluster.
Bacterial Identiﬁcation and Susceptibility Testing
CPE screening was performed as previously reported.19,20
Brieﬂy, a stool or rectal swab with visible fecal staining was
submerged into brain heart infusion broth supplemented with
10mg/L vancomycin (Sigma Aldrich) and 0.5mg/L
meropenem (Hospira), incubated at 37°C overnight for
enrichment. Ten microliters of the enriched broth was sub-
cultured onto MacConkey agar with 2 µg/mL meropenem and
incubated aerobically at 35°C for 48 hours. Enterobacteriaceae
that grew on the selective agars were identiﬁed using matrix-
assisted laser desorption ionization-time of ﬂight mass spec-
trometry (Bruker Daltonics). Antimicrobial susceptibilities of
the Enterobacteriaceae were determined using the Kirby-Bauer
disk diffusion method in accordance with the Clinical and
Laboratory Standards Institute or manufacturer’s instructions.
The presence of carbapenemase in the isolates was screened
using the combined-disc test (meropenem/imipenem/ertape-
nem alone vs combination with phenyl boronic acid or
ethylenediaminetetraacetic acid) and multiplex polymerase
chain reaction targeting blaNDM, blaKPC, and blaOXA, blaIMP,
blaVIM, blaGES, blaIMI, and blaSME genes.
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Statistical Analysis
A logistic regression model was used to determine the risk
factors of gastrointestinal colonization of CPE. An odds ratio
signiﬁcantly greater than 1 implied higher risk of having
gastrointestinal colonization of CPE. Cox regression was used
to analyze risk factors of persistent colonization of CPE. CPE
clearance was deﬁned as the event. A hazard ratio of less than 1
implied longer duration of CPE colonization. Both bivariable
and multivariable analyses were conducted. Multivariable
analyses began with the full model and backward elimination
was applied to select the ﬁnal model. SPSS, version 20 (IBM),
was used to perform the statistical analyses. A level of sig-
niﬁcance at 5% was adopted.
results
From July 1, 2011, through December 31, 2015, a total of
66,672 fecal specimens from 31,526 patients were screened in
our healthcare network, of which 1,374 specimens (2.1%)
from 518 patients (1.6%) were positive for CRE, and 345
use of proton pump inhibitors and cpe 1419
specimens (0.5%) from 100 patients (0.3%) were positive for
CPE (Figure 1). The overall prevalence of CRE and CPE was
15.0 and 2.9 per 100,000 patient-days, respectively. The
number and prevalence (per 100,000 patient-days) of CRE
increased from 17 (2.2) in 2012 to 268 (33.9) in 2015
(P< .001), whereas the corresponding ﬁgures of CPE
increased from 2 (0.3) to 63 (8.0) (P< .001), respectively. Of
the 100 patients newly identiﬁed with gastrointestinal coloni-
zation of CPE, there were 69 males with a median (range) age
of 60 (1–97) years. There were 48 medical patients (48%), 31
surgical patients, 10 orthopedic patients, 5 pediatric patients,
2 oncology patients, and another 4 patients who stayed in the
adult intensive care unit. Thirty-seven (37%) of 100 patients
had nosocomial onset of CPE with a median (range) of 15
(3–40) days after hospitalization. Twenty-one (56.8%) of the
37 patients with nosocomial onset of CPE were identiﬁed from
opportunistic and safety net screening from 17 different wards;
the remaining 16 (43.2%) had nosocomial acquisition of CPE
identiﬁed as secondary cases during contact tracing in 14
wards. There was no evidence of clustering of cases to suggest
hospital outbreaks. The risk factors for gastrointestinal
colonization with CPE are shown in Table 1. The presence of
wound or drain and the use of cephalosporins, carbapenems,
and PPIs in the preceding 6 months were independent risk
factors in the multivariable analysis.
More than 1 specimen was received from 79 patients for
CPE screening, with the median (range) follow-up time of 33
(3–545) days. Spontaneous clearance of CPE was noted in
57 (72.2%) of 79 patients, with a median (range) of 30 (3–411)
days during our study period. Consumption of both anti-
biotics and PPIs after CPE identiﬁcation was associated with
later clearance of CPE (hazard ratio, 0.35 [95% CI, 0.17–0.73])
(Table 2), compared with patients without use of both anti-
biotics and PPIs. On the other hand, the use of both antibiotics
and PPIs in the 6 months preceding CPE identiﬁcation was not
signiﬁcantly associated with the duration of clearance of CPE
ﬁgure 1. Screening of gastrointestinal colonization of carbapenemase-producing Enterobacteriaceae (CPE) in Hong Kong West Cluster
(July 1, 2011, through December 31, 2015). Target admission screening includes (i) “Whom TO screen” criteria, where T represents a
history of medical “tourism” with hospitalization outside Hong Kong and O represents a history of receiving surgical operation outside
Hong Kong within 12 months preceding admission, (ii) patients with histories of admissions to local hospitals in the past 3 months, and
(iii) patients being admitted to high-risk areas, including intensive care unit, liver transplant unit, hematology unit, and renal dialysis unit.
Opportunistic screening for CPE is added on all fecal specimens requested for Clostridium difﬁcile culture or cytotoxin assay, whereas safety
net screening represents testing for CPE in all patients on the 14th day of hospitalization. Extensive contact tracing for secondary cases was
performed when a CPE-carrying index patient was identiﬁed. Extensive contact tracing included all potentially exposed patients during the
entire period of hospitalization of the index patient. Of 63 patients with CPE diagnosed by targeted screening, 26 (41%) had history of
hospitalization outside Hong Kong in the preceding 12 months (24 from China, 1 from Thailand, and 1 from India), whereas 34 (54%) had
history of hospitalization in Hong Kong in the preceding 3 months. The remaining 3 patients had no history of hospitalization and had
probably acquired CPE in the community from an unknown source.
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table 1. Risk Factors for Gastrointestinal Colonization of Carbapenemase-Producing Enterobacteriaceae (CPE)
Bivariable analysis Multivariable analysisa
Characteristic
Patients with gastrointestinal
colonization of CPE (n= 100)
Patients without gastrointestinal
colonization of CPE (n= 400)
Odds ratio
(95% CI) P value Odds ratio (95% CI) P value
Age, mean ± SD, y 59.4± 20.8 58.9± 24.3 1.00 (0.99–1.01) .865
Male sex 69 (69.0) 213 (53.3) 1.95 (1.23–3.12) .005 1.91 (1.15–3.18) .013
Resident in long-term care facilities 7 (7.0) 35 (8.8) 0.79 (0.34–1.82) .573
Presence of indwelling device
Nasogastric tube 11 (11.0) 19 (4.8) 2.48 (1.14–5.39) .022
Tracheostomy or endotracheal tube 9 (9.0) 8 (2.0) 4.85 (1.82–12.90) .002
Urinary catheter 33 (33.0) 90 (22.5) 1.70 (1.05–2.74) .030
Wound or drain 29 (29.0) 36 (9.0) 4.13 (2.38–7.17) <.001 3.12 (1.70–5.71) <.001
Presence of chronic diseasesb 50 (50.0) 196 (49.0) 1.04 (0.67–1.61) .858
Use of antibiotics in preceding 6 monthsc
Beta-lactam/ beta-lactamase inhibitors 39 (39.0) 58 (14.5) 3.77 (2.31–6.15) <.001
Cephalosporins 20 (20.0) 17 (4.3) 5.63 (2.83–11.23) <.001 3.06 (1.42–6.59) .004
Carbapenems 22 (22.0) 26 (6.5) 4.06 (2.19–7.53) <.001 2.21 (1.10–4.48) .027
Fluoroquinolones 12 (12.0) 23 (5.8) 2.24 (1.07–4.66) .032
Use of proton pump inhibitors in
preceding 6 monthsd
60 (60) 105 (26.3) 4.21 (2.67–6.66) <.001 2.84 (1.72–4.71) <.001
History of hospitalization in past 6 months 80 (80.0) 278 (69.5) 1.76 (1.03–2.99) .039
NOTE. Data are no. (%) unless otherwise speciﬁed.
aFinal model was selected by backward selection procedure with the full model including all the variables examined in the bivariable analysis. The Hosmer-Lemeshow goodness-of-ﬁt
statistics= 0.188, P= .996.
bChronic diseases include chronic cerebral conditions, chronic cardiopulmonary conditions, chronic renal failure, liver cirrhosis, diabetes mellitus, and malignant tumors.
cAntibiotic use variables were assessed as binary variables, instead of quantitative variables. In usual circumstances, using variables in a quantitative manner (ie, taking the duration of
exposure into account) would be more informative. Unfortunately, there was overrepresentation of zeros in the variables, such that using the variables as quantitative variables in the
logistic regression model resulted in an unacceptable goodness-of-ﬁt. With binary variables, it could be possible that true differences between the case and control groups were not
detected or were greater than what was detected.
dThe proton pump inhibitors included dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole.
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(P= .742). The cumulative distribution plot of clearance of
CPE patients with and without use of antibiotics and/or PPIs is
illustrated in Figure 2.
Of the 100 patients with gastrointestinal colonization of
CPE, 10 (10%) had isolation of CPE from clinical specimens,
after a median (range) duration of 55 (1–482) days. Six
patients had CPE isolated in urine, 1 in bile, 1 in sputum, 1 in
wound, and 1 in both blood and sputum specimens. Nine
(9%) of the 100 patients died during the same episode of
hospitalization in which CPE was identiﬁed.
Molecular characterization of the 100 ﬁrst isolates of
patient-unique CPE strains is illustrated in Table 3. One
patient had multiple NDM-producing Enterobacteriaceae
isolates, including Escherichia coli, Salmonella species, and
Proteus mirabilis, during the course of hospitalization as we
reported previously.20
discussion
The overall prevalence of gastrointestinal colonization of CRE
(1.6%) in our hospital network was much lower than that
reported in previous studies conducted in the healthcare facil-
ities in the United States (5.4%),21 mainland China (6.6%),22
and Israel (12.0%).23 However, the prevalence of CRE and CPE
increased signiﬁcantly between 2012 and 2015, by 15- and
30-fold, respectively. More than 20% of the patients with CRE
isolates had carbapenemase-producing strains in 2015, which
was twice that reported in our group’s previous study.19
Multiple sources of CPE acquisition were noted in our cohort.
Approximately 25% of new cases had a history of hospitaliza-
tion outside Hong Kong, especially in mainland China, where
CPE was recently reported in both metropolitan and rural
healthcare settings.24,25 The route of acquisition inmost patients
was uncertain, except for a minority with clear epidemiologic
link suggestive of nosocomial transmission during the extensive
contact tracing exercise as previously described.11,26 The possi-
bility of community acquisition could not be excluded.
Carbapenemase-producing microorganisms have been reported
in food-producing animals and food products.27,28 Avoidance
of undercooked food items and vigilant attention to kitchen
hygiene to prevent cross-contamination are advisable to reduce
the risk of acquisition of multidrug-resistant organisms.29
table 2. Hazard Ratios (HRs) for Clearance of Carbapenemase-Producing Enterobacteriaceae (CPE) by Epidemiologic Characteristics of
79 Patients With >1 Specimen Requested for CPE Screening
Bivariable analysis Multivariable analysisa
Characteristic Value HR (95% CI) P value HR (95% CI) P value
Age, mean ± SD, y 60.9±21.1 1.00 (0.99–1.01) .793
Male sex 54 (68.4) 0.84 (0.48–1.45) .528
Resident in long-term care facilities 7 (8.9) 1.89 (0.73–4.89) .190
Presence of nasogastric tube 10 (12.7) 1.45 (0.71–2.98) .311
Presence of tracheostomy or endotracheal tube 9 (11.4) 0.90 (0.40–2.00) .795
Presence of urinary catheter 30 (38.0) 1.55 (0.90–2.65) .113
Presence of wound or drain 26 (32.9) 1.41 (0.82–2.42) .212
Presence of chronic diseasesb 39 (49.4) 1.03 (0.61–1.74) .923
History of hospitalization in 6 months before
diagnosis of CPE colonization
64 (81.0) 0.60 (0.30–1.18) .138
Use of antibioticsc and/or proton pump inhibitorsd in preceding 6 months before diagnosis of CPE colonization
Neither antibiotics or proton pump inhibitors 20 (25.3) 1 [Reference]
Antibiotics only 7 (8.9) 0.87 (0.31–2.44) .789
Proton pump inhibitors only 12 (15.2) 1.03 (0.44–2.41) .945
Both antibiotics and proton pump inhibitors 40 (50.6) 0.90 (0.47–1.72) .742
Use of antibioticsc and/or proton pump inhibitorsd within 1 month after diagnosis of CPE colonization
Neither antibiotics or proton pump inhibitors 18 (22.8) 1 [Reference] 1 [Reference]
Antibiotics only 10 (12.7) 0.67 (0.28–1.60) .364 0.67 (0.28–1.60) .364
Proton pump inhibitors only 23 (29.1) 0.64 (0.31–1.30) .213 0.64 (0.31–1.30) .213
Both antibiotics and proton pump inhibitors 28 (35.4) 0.35 (0.17–0.73) .005 0.35 (0.17–0.73) .005
NOTE. Data are no. (%) unless otherwise speciﬁed.
aFinal model was selected by backward selection procedure with the full model including all the variables examined in the bivariable analysis, and
only 1 variable was retained in the ﬁnal model.
bChronic diseases include chronic cerebral conditions, chronic cardiopulmonary conditions, chronic renal failure, liver cirrhosis, diabetes
mellitus, and malignant tumors.
cThe antibiotics included beta-lactam/ beta-lactamase inhibitors, cephalosporins, carbapenems, and ﬂuoroquinolones.
dThe proton pump inhibitors included dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole.
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Opportunistic and safety net screening detected a signiﬁcant
proportion of CPE cases who were not colonized at the time of
admission but acquired CPE during hospitalization.
Broad-spectrum antibiotics were not infrequently used in
patients with prolonged hospitalization. These screening
strategies facilitated the identiﬁcation of CPE carriage in
patients with low microbial load upon admission, which was
similar to the detection of MRSA in our group’s previous
study.30 In fact, use of broad-spectrum antibiotics such as
cephalosporins and carbapenems was signiﬁcantly associated
with CPE acquisition in the multivariable analysis, similar to
ﬁndings in previous studies of gastrointestinal colonization of
CPE during active surveillance cultures.31,32 Use of
broad-spectrum antibiotics without intrinsic activity against
CPE contributed to prolonged colonization. The duration of
gastrointestinal colonization of CPE varied from months to
years. After a large, single-center outbreak of KPC-producing
Klebsiella pneumoniae in Germany, most patients had sponta-
neous decolonization within 6 months after acquisition, but
long-term carriage of more than 3 years was possible.33
To the best of our knowledge, our study was the ﬁrst to
demonstrate that use of PPIs was a risk factor for CPE acqui-
sition. In addition, the combination of broad-spectrum anti-
biotics and PPI consumption further delayed CPE clearance.
PPIs were previously shown to alter the composition of the gut
microbiota by lowering the abundance of gut commensals,
reducing microbial diversity,34 and encouraging bacterial
overgrowth in the small intestine, resulting in an overall
increased risk of recurrent aspiration pneumonia in the
elderly35 and C. difﬁcile–associated diarrhea.36 Concomitant
use of antibiotics and PPIs also conferred a greater risk of
C. difﬁcile infection.37 Although the mechanism of PPI use and
gastrointestinal colonization of CPE remains uncertain,
hypochlorhydria induced by PPIs38 may have allowed the
passage of CPE from oral intake, nasogastric tube, or percu-
taneous gastrostomy feeding to the lower intestine with
colonization during hospitalization. Thus, it is conceivable that
not just antibiotics but also PPIs may increase the microbial
load of CPE within the gastrointestinal tract of these patients
and prolong the duration of CPE carriage. Therefore, directly
observed patient hand hygiene before meals and medications
among hospitalized patients, especially in patients receiving
concurrent broad-spectrum antibiotics and PPIs, is important
because it reduces the risk of oral ingestion of CPE. Similarly,
healthcare workers should comply with hand hygiene practice
before preparing feeds for patients with nasogastric or percu-
taneous gastrostomy. Male patients were shown to be
signiﬁcantly associated with CPE carriage, possibly related to
the gender difference in hand hygiene practice, in which
females washed their hands signiﬁcantly more often than
males.39 Results from this study supported the need for
limiting use of broad-spectrum antibiotics and PPIs in patients
with gastrointestinal colonization with CPE to facilitate
spontaneous clearance. Whether histamine H-2 receptor
blocker, which has less profound acid suppression, would have
lesser effect on CPE colonization requires further investiga-
tion. Although we hypothesized that PPI use could be asso-
ciated with CPE acquisition and colonization, a previous study
has not found any association between PPIs and CRE acqui-
sition.21 Further study of this potential risk factor is warranted.
ﬁgure 2. Cumulative clearance of carbapenemase-producing
Enterobacteriaceae (CPE) patients with use of antibiotics and
proton pump inhibitors (PPIs). Data on the use of PPIs and
antibiotics without activities against CPE in patients after diagnosis
of CPE gastrointestinal colonization.
table 3. Molecular Characteristics of the First Isolate of Patient-
Unique Strain of Carbapenemase-Producing Enterobacteriaceae
Isolated From 100 Patients
Type of β-lactamase Organisms Number
New Delhi metallo-β-lactamase
(NDM)
Escherichia coli 56
Klebsiella
pneumoniae
10
Enterobacter
aerogenes
2
Enterobacter cloacae 2
Citrobacter koseri 1
Citrobacter freundii 1
Raoultella species 1
K. pneumoniae carbapenemase (KPC) K. pneumoniae 20
Enterobacter species 1
Metallo-β-lactamase (IMP) K. pneumoniae 4
E. cloacae 1
Oxacillinase metallo-β-lactamase
(OXA)
E. coli 1
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There are several limitations of this study. First, the
relatively small sample size may be inadequate to demonstrate
other signiﬁcant associations—for instance, the use of either
antibiotics or PPIs after CPE identiﬁcation on the duration of
CPE colonization. Second, our strains of CPE were hetero-
geneous, comprising NDM-, KPC-, IMP-, and OXA-
producing Enterobacteriaceae. However, we believe that the
analysis of the clinical epidemiology in this group of patients
provides useful information for the formulation of infection
control policy, regardless of the actual molecular type of CPE.
In summary, compliance with infection control and hand
hygiene is particularly important for relevant healthcare
workers and patients on concomitant treatment with anti-
biotics and PPIs, which predispose them to a more prolonged
carriage of CPE.
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